Collegium Pharmaceutical (COLL) Expected to Announce Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $1.86 per share and revenue of $216.03 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.68 earnings per share. On average, analysts expect Collegium Pharmaceutical to post $6.42 EPS for the current fiscal year and $5.89 EPS for the next fiscal year.

Collegium Pharmaceutical Trading Down 0.5%

COLL stock opened at $23.68 on Tuesday. The company has a market capitalization of $771.02 million, a PE ratio of 19.10, a P/E/G ratio of 0.72 and a beta of 0.73. Collegium Pharmaceutical has a 12 month low of $21.43 and a 12 month high of $50.79. The firm’s 50-day moving average is $23.23 and its 200 day moving average is $33.24. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84.

Analyst Ratings Changes

COLL has been the subject of several research reports. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Truist Financial assumed coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 target price on the stock. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price on the stock. Zacks Research raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $48.71.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.